$12 Billion Valuation

OpenEvidence Secures $250 Million in Fresh Investment OpenEvidence, a rapidly growing AI-driven healthcare technology startup, has reached a massive $12 billion valuation following a new $250 million Series D funding round. The investment was co-led by prominent venture capital firms Thrive Capital and DST, signaling strong investor confidence in the company’s future despite rising competition in AI-powered health information platforms. This latest funding round marks a significant milestone for the U.S.-based startup and further strengthens its position in the evolving artificial intelligence healthcare market. Valuation Doubles in Just a Few Months The new valuation represents a 100% increase compared to OpenEvidence’s previous funding round in October, when it raised $200 million at a $6 billion valuation, led by Google Ventures (GV). In less than a year, the company has demonstrated exceptional growth, both in user adoption and revenue generation. According to company disclosures, OpenEvidence has now raised a total of $700 million across multiple funding rounds, placing it among the most well-funded AI health startups in the United States. Backed by Leading Investors and Institutions OpenEvidence’s investor list reads like a who’s who of Silicon Valley and healthcare innovation. Major backers include: The continued support from top venture capital firms and healthcare institutions suggests that investors are not overly concerned about competition from emerging AI health products developed by companies like OpenAI and Anthropic. AI-Powered Medical Platform Built for Doctors OpenEvidence is an AI-powered medical information platform designed specifically for licensed healthcare professionals. Often compared to WebMD for doctors, the platform delivers evidence-based clinical insights, medical literature summaries, and real-time decision support. Unlike consumer-focused AI health tools, OpenEvidence is tailored to clinical use, helping physicians make faster and more informed medical decisions. This differentiates it from ChatGPT’s health features, which primarily target everyday consumers. Competitive Landscape: OpenEvidence vs AI Health Rivals While OpenEvidence operates in the same broader space as AI health solutions from OpenAI and Anthropic, its target audience sets it apart. Anthropic’s Claude for Healthcare serves patients, providers, and payers, whereas OpenEvidence remains deeply focused on verified U.S. medical professionals. This specialized approach appears to be paying off, as the company continues to grow rapidly despite increased competition in the healthcare artificial intelligence sector. Massive Growth in Clinical Usage OpenEvidence revealed impressive usage metrics, highlighting its fast-growing adoption among medical professionals. In December alone, the platform supported 18 million clinical consultations conducted by verified healthcare providers in the United States. This marks a dramatic increase compared to approximately 3 million monthly searches just one year ago, showcasing the platform’s accelerating momentum and trust within the medical community. Revenue Crosses $100 Million Milestone In addition to user growth, OpenEvidence confirmed that it has surpassed $100 million in annual revenue, a key indicator of strong product-market fit. The platform currently operates on a free, ad-supported model, allowing widespread access for clinicians while generating sustainable income. This revenue milestone further reinforces the company’s long-term business viability and attractiveness to investors. The Future of AI in Healthcare Information With its latest funding round, OpenEvidence is well-positioned to expand its AI capabilities, enhance clinical accuracy, and potentially enter new healthcare markets. As artificial intelligence continues to transform medical research and decision-making, platforms like OpenEvidence are becoming essential tools for modern healthcare systems. The company’s rapid rise underscores a broader trend: AI-powered medical information platforms are no longer optional—they are becoming critical infrastructure in healthcare. For more breaking technology news, AI startup updates, and innovation stories from the U.S. tech ecosystem, stay connected with TechCes.com 🚀